MarketPulse

clinical efficacy

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Evaxion's Personalized Cancer Vaccine Shows 75% Response Rate in Extended Trial

Evaxion completes Phase 2 extension of personalized cancer vaccine EVX-01 with 75% response rate and 92% durability at two years.
MRKEVAXphase 2 trialimmunotherapy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Organogenesis Wins Key Trial for Diabetic Ulcer Treatment, Bolstering PuraPly®AM Case

Organogenesis's PuraPly®AM met primary endpoint in diabetic ulcer trial with statistically significant 12-week wound closure, supporting future insurance coverage expansion.
ORGOregenerative medicinerandomized controlled trial
BenzingaBenzinga··Vandana Singh

Lyme Vaccine Setback: Valneva-Pfizer Trial Misses Primary Goal But Eyes Regulatory Path

Valneva-Pfizer Lyme vaccine trial misses primary endpoint but shows 73-75% secondary efficacy; Pfizer to seek regulatory approval despite setback. Valneva shares fell 35.27%.
PFEVALNstock declinePhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Bridgebio Pharma, Inc.

BridgeBio's BBP-418 Shows Promise as First-Ever LGMD2I/R9 Treatment

BridgeBio reports positive Phase 3 results for BBP-418, showing 31-second improvement in walking tests. FDA submission expected H1 2026, potential U.S. launch late 2026/early 2027.
BBIOFDA approvaldrug development
BenzingaBenzinga··Vandana Singh

Teva and Sanofi Report Positive Phase 3 Results for Duvakitug IBD Treatment

Teva and Sanofi report positive Phase 3 results for duvakitug IBD treatment, with over 55% of patients meeting efficacy endpoints. Stock rises 2.85%.
SNYTEVAmonoclonal antibodyclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Teva

Sanofi and Teva Report Sustained Efficacy for Duvakitug in IBD Maintenance Study

Sanofi and Teva report duvakitug maintains efficacy in IBD maintenance trial, with remission rates of 47-58% in ulcerative colitis. Drug advances to Phase III development.
SNYTEVAmonoclonal antibodyinflammatory bowel disease